AccuStem Sciences Inc. announced a pilot study agreement with the National Surgical Adjuvant Breast and Bowel Project (NSABP) to evaluate its StemPrintER 20‑gene prognostic assay in a subset of patients from the NSABP B‑32 cohort.
The B‑32 trial enrolled more than 5,000 early‑stage breast cancer patients between May 1999 and February 2004, comparing sentinel lymph node resection to full axillary lymph node dissection. Using this well‑characterized dataset allows AccuStem to assess StemPrintER’s predictive power across a large, diverse population.
StemPrintER measures tumor “stemness” with a 20‑gene panel; prior studies have shown that patients with high stemness are up to four times more likely to experience distant recurrence. The pilot will stratify patients by recurrence risk to determine whether the assay can guide surgical decision‑making and reduce unnecessary axillary dissections.
AccuStem CEO Wendy Blosser said the partnership will help confirm that StemPrintER can inform surgical planning and potentially reduce complications such as lymphedema, improving patient outcomes.
The agreement represents a key step toward regulatory and commercial acceptance in the U.S. market, expanding the assay’s validation beyond earlier studies and positioning it for broader adoption.
While financial terms and the exact subset size were not disclosed, the collaboration with NSABP—a leader in breast cancer research—lends credibility and could accelerate market entry.
The partnership could differentiate StemPrintER from other prognostic tests, such as OncotypeDX, and position AccuStem to capture market share in the growing precision oncology diagnostics space.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.